Online inquiry

IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3223MR)

This product GTTS-WQ3223MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3223MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8340MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ8479MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ13718MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ14646MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ14675MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ10356MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ2046MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ10215MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW